Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616614 · ClinicalTrials.gov registry record · Phase 3
Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 862
- Enrollment target
NCT02616614 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 862 participants.
The verdict
NCT02616614, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 862 participants
- Enrollment target
Study Summary
Actavis has developed a generic formulation of clindamycin 1.2% and benzoyl peroxide 3.75% gel. This study is designed to evaluate the safety and efficacy of this formulation in subjects with Acne Vulgaris
Interventions
- DRUG Placebo
- DRUG Onexton
- DRUG Clindamycin/benzoyl peroxide gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 862 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02616614
The ClinicalTrials.gov registry entry for NCT02616614 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 862 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02616614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02616614 about?
NCT02616614 is a clinical study titled "Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris". Actavis has developed a generic formulation of clindamycin 1.2% and benzoyl peroxide 3.75% gel. This study is designed to evaluate the safety and efficacy of this formulation in subjects with Acne Vulgaris
What is the current status of trial NCT02616614?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 862 participants. The study started on 2015-05. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02616614?
The interventions under investigation include: Placebo (DRUG), Onexton (DRUG), Clindamycin/benzoyl peroxide gel (DRUG).
Who is sponsoring clinical trial NCT02616614?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.